Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial — M. Angelyn Bethel (2019) | RDL Network
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
Article 2019 en
Authors
MB
M. Angelyn Bethel
RM
Robert J. Mentz
PM
Peter Merrill
Abstract
1 min read
EQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m<sup>2</sup> in analyses unadjusted for multiplicity.
Giuseppe Boriani, Marco Proietti, C Laroche, Igor Diemberger, Zbigniew Kalarus, Tatjana Potpara, Laurent Fauchier, Harry J.G.M. Crijns, Aldo P. Maggioni, Professor Gregory Lip
Fozia Ahmed, Paul R. Kalra, John G.F. Cleland, Abdallah Al‐Mohammad, Andrew L. Clark, Victor Chong, Alan G. Japp, Rebecca Lane, Stephen J Leslie, Iain C. Macdougall, Thuraia Nageh, Rajiv Sankaranarayanan, Jolanta Sobolewska, Aaron Wong, Elizabeth Thomson, Mark C. Petrie, Iain Squire, Ian Ford, Philip A. Kalra
Discussion(0)
No comments yet. Be the first to comment.